Early ketamine for pain in young people with sickle cell disease
Tests early ketamine for pain from sickle cell disease, checking hospital admission.
Key facts
- Who runs it
- Boston Children's Hospital
- Where
- Brookline, United StatesSee the site
- Trial code
- Registry title
- Optimal Timing of Ketamine Initiation for SCD Pain
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 90 people, planned
- Started
- Feb 2026
- Expected to end
- Feb 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ketamine hydrochloride injection
- Placebo
- Record updated
- 9 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults with sickle cell disease who come to the emergency department or infusion clinic with pain.
- Age
- 6 to 24 years old
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease with pain at the time of the visit to the emergency department or infusion clinic.
Main reasons for not taking part
- Allergy to ketamine
- Severe side effects from ketamine in the past
- Unable to give consent
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- sickle cell disease diagnosis
- presenting with pain to ED or infusion clinic
- patient at study site
- 6 to 24 years old
Who cannot take part
- allergy to ketamine
- severe side effects associated with ketamine
- unable to consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 24 years old?
Where in United States
- Boston Children's HospitalBrookline, United StatesContact: Natasha ArcherNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if the use of early ketamine decreases the chance of admission to the hospital in patients with sickle cell disease presenting with pain.
Read full original descriptionShow less
The main questions this study aims to answer are:
* Does ketamine given within 1 hour of acute care presentation decrease the chance of hospital admission? * If admitted, does continuing ketamine in the first few hours of admission decrease opioid use or length of stay compared to those who start it later in the admission?
Researchers will compare the study arm to patients with sickle cell disease who receive placebo within 1 hour of presentation for the first aim.
Participants will be given ketamine/placebo by mouth without 1 hour of presentation.
If admitted, all participants will be able to start open label IV ketamine upon admission to the floor based on their clinical needs. Participants who end up starting ketamine will be reviewed to determine if early start to ketamine is helpful in reducing opioid use and length of stay.
The 2 groups in the trial
- Oral KetamineTreatment being tested
Single dose of oral ketamine 0.5mg/kg (max dose of 35mg)
Treatment: Ketamine hydrochloride injection
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Double-blind, Randomized, Placebo Controlled Study to Evaluate Optimal Timing of Ketamine Initiation
- Plain-language title
- Early ketamine for pain in young people with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07450430, who can take part
- Record updated
- 9 March 2026